Biology Reference
In-Depth Information
29. Estenne M, Hertz MI (2002) Bronchiolitis obliterans after human lung transplantation. Am J
Respir Crit Care Med 166(4):440-444
30. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Mohacsi PJ, Keck BM et al (2003) The
registry of the International Society for Heart and Lung Transplantation: twentieth official
adult lung and heart-lung transplant report-2003. J Heart Lung Transplant 22(6):625-635
31. Estenne M, Egan JJ, Mallory GB, Yousem S (2002) Bronchiolitis Obliterans Syndrome 2001:
an update of the diagnostic criteria. J Heart Lung Transplant 21(3):297-310
32. Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D et al (2005) Clinical
impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung trans-
plant. Am J Transplant 5:2031-2036
33. Gottlieb J, Schulz TF, Welte T, Fuehner T, Dierich M, Simon AR et al (2009) Community-
acquired respiratory viral infections in lung transplant recipients: a single season cohort study.
Transplantation 87:1530-1537
34. Milstone AP, Brumble LM, Barnes J, Estes W, Loyd JE, Pierson RNI et al (2006) A single-
season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir
J 28:131-137
35. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP et al
(2004) Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and
death. Am J Respir Crit Care Med 170:181-187
36. Hopkins P, McNeil K, Kermeen F, Musk M, McQueen E, MacKay I et al (2008) Human
metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus.
Am J Respir Crit Care Med 178:876-881
37. Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, DeVincenzo J et al (2011) RNA inter-
ference therapy in lung transplant patients infected with respiratory syncytial virus. Am J
Respir Crit Care Med 183(4):531-538
38. Hall WJ, Hall CB, Speers DM (1978) Respiratory syncytial virus infection in adults: clinical,
virologic, and serial pulmonary function studies. Ann Intern Med 88(2):203-205
39. Duncan CB, Walsh EE, Peterson DR, Lee FE, Falsey AR (2009) Risk factors for respiratory
failure associated with respiratory syncytial virus infection in adults. J Infect Dis
200(8):1242-1246
40. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA
delivery. Nat Rev Drug Discov 8(2):129-138
41. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R et al (2010) A status
report on RNAi therapeutics. Silence 1(1):14
42. Fitzgerald K, Frank-Kamenetsky M, Mant T, Ritter J, Chiesa J, Munasamy M, Hutabarat R,
Clausen V, Watkins D, Smith K, Sutherland J, Cehelsky J, Nochur S, Binne L, Nechev L,
Kretschmer M, Karsten V, Vaishnaw A, Simon A (2012) Phase I safety, pharmacokinetic and
pharmacodynamic results for ALN-PCS, a novel RNAi therapeutic for the treatment of hyper-
cholesterolemia. American Heart Association's Arteriosclerosis, Thrombosis and Vascular
Biology [Abstract]; Scientific Sessions
43. Coelho T, Silva A, Suhr OB, Adams D, Lozeron P, Hawkins P, Mant T, Falzone R, Figeruoa Y,
Hutabarat R, Butler J, Fishman S, Chen Q, Costelha S, Saraiva MJ, Cehelsky J, Vaishnaw A,
Gollob J, Sah DWY (2012) Final Phase I safety, pharmacokinetic and pharmacodynamic
results for ALN-TTR01, a novel RNAi therapeutic for the treatment of transthyretin amyloido-
sis. XIII international symposium on amyloidosis